Develops DNase technology for use alongside cancer treatments for patients with pancreatic and other solid tumors, and licenses its PolyXen drug-delivery platform to pharmaceutical and biotechnology companies.
10-K for FY2025, filed Mar 12, 2026We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. Our…View ↗
We are focused on advancing the development of our DNase technology toward a first-in-human, multicenter, dose escalation and…View ↗
We have partnered with biotechnology and pharmaceutical companies to develop our proprietary drug delivery platform, PolyXen, and receive…View ↗
Partners pay for licenses and collaboration work through upfront fees and development or regulatory milestones; royalties are tied to partner product sales and earned in the period of sale, while some license payments are spread over service periods.
10-K for FY2025, filed Mar 12, 2026The Company enters into supply, license and collaboration arrangements with pharmaceutical and biotechnology partners, some of which…View ↗
The terms of the Company’s license agreements may include delivery of an intellectual property license to a collaboration partner. The…View ↗
The Company expects to recognize royalty revenue in the period of sale, based on the underlying contract terms, provided that the reported…View ↗
$3M
10-K for FY2025, filed Mar 12, 2026
$3M ↗
Pharmaceutical and biotechnology companies work with Xenetic through supply, license and collaboration arrangements; Serum Institute holds an exclusive PolyXen license, with royalties tied to sales to its customers in its territory.
10-K for FY2025, filed Mar 12, 2026
No. It lost $2.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$1.7MView ↗
8-K, filed Nov 13, 2026
Announced Definitive Exchange Agreement with Santersus AG: Entered into a definitive share exchange agreement to, subject to Xenetic’s…View ↗
Growing. Revenue grew 2.6x in 4 years, from $1.2M in FY2021 to $3M in FY2025, about 27% a year.
Competes with Merck
10-K for FY2025, filed Mar 12, 2026In the field of pancreatic cancer, we will compete with the few, currently approved treatments for pancreatic carcinoma, including…View ↗
Loading...